Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Dr. Reddy’s Fondaparinux Sodium Injection

By Pharmaceutical Processing | July 13, 2011

 

Dr. Reddy’s Laboratories and Alchemia Limited, Brisbane, Australia
announced today that Dr. Reddy’s has received final approval of Dr. Reddy’s
ANDA for Fondaparinux Sodium Injection, a bioequivalent generic version of
Arixtra(R), in the US market on July 11, 2011 by FDA. The approval covers 2.5
mg/ 0.5 mL, 5.0 mg/ 0.4 mL, 7.5 mg/ 0.6 mL and 10 mg/ 0.8 mL doses of the drug
in prefilled color-coded, single-dose syringes with automatic needle safety
device. Dr. Reddy’s will manufacture fondaparinux under license using a
patented process developed by Alchemia.

Commenting on the approval, G.V. Prasad, Vice-Chairman and
CEO of Dr. Reddy’s, said, “The fondaparinux approval demonstrates the
strong technical capabilities of the teams at Dr. Reddy’s and Alchemia. Given that
this is a complex generic molecule which is difficult to manufacture at scale,
competition is likely to be limited for the foreseeable future. Accordingly,
from a commercial perspective, Dr. Reddy’s will promptly execute a phased
launch that initially plays to our strengths in select wholesale and retail
outlets, and subsequently enhance share over time in the coming quarters to
augment the growing annuity of upsides in our North America Generics
business.”

Pete Smith, CEO of Alchemia, said, “This collaboration
has succeeded due to the expertise, dedication, and close communication between
the teams at both companies. This approval is a major milestone for Alchemia,
fondaparinux representing a significant source of potential future income for
the company.”

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE